Annexon, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $ANNX in the last 30 days.
See all $ANNX insider activity →Annexin Pharmaceuticals AB (ANNX) has finished enrolling 12 patients in its Phase 2a NEXUS study of vanexin. The company expects topline data by the end of Q1 2027, according to the press release.
H.C. Wainwright raised its price target for Annexon Biosciences (ANNX) to $25, citing catalysts like the tanruprubart BLA submission for GBS and ARCHER II readout for vonaprument. The firm values these at $11.70 and $13.60 per share, respectively. ANNX trades at $3.96, down 38% in six months, with a strong balance sheet but high cash burn. Recent Q2 loss was $0.28 per share. Other analysts also raised targets and ratings.
Analysts updated price targets for several companies. Bernstein raised Microsoft's target to $662, maintaining an Outperform rating. Morgan Stanley increased Global-E Online's target to $50 and upgraded it to Overweight. Other notable changes include Truist Financial, Annexon, Ameriprise Financial, Lyft, A O Smith, Hudson Pacific Properties, Boyd Gaming, and Veradermics.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning ANNX (Annexon, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent ANNX coverage spans financial news, earnings and technology.
Enrollment completion removes a near‑term uncertainty and sets the stage for topline data, which could drive the stock higher if results are positive.
Analyst upgrade and higher price target suggest upside potential.
Target increase signals confidence.
HC Wainwright & Co. maintained a Buy rating and $25 price target for Annexon, implying a 633.1% upside from the Oct 16 close of $3.41. The firm highlighted Annexon's pipeline targeting unmet medical needs in autoimmune and neurodegenerative diseases.
Insider purchase suggests confidence, potential upside pressure.
AlphAI scores every news story that mentions ANNX with an AI model for sentiment and relevance, and aggregates insider trades from Annexon, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Annexin Pharmaceuticals AB (ANNX) has finished enrolling 12 patients in its Phase 2a NEXUS study of vanexin. The company expects topline data by the end of Q1 2027, according to the press release.
1 min readH.C. Wainwright raised its price target for Annexon Biosciences (ANNX) to $25, citing catalysts like the tanruprubart BLA submission for GBS and ARCHER II readout for vonaprument. The firm values these at $11.70 and $13.60 per share, respectively. ANNX trades at $3.96, down 38% in six months, with a strong balance sheet but high cash burn. Recent Q2 loss was $0.28 per share. Other analysts also raised targets and ratings.
2 min readAnalysts updated price targets for several companies. Bernstein raised Microsoft's target to $662, maintaining an Outperform rating. Morgan Stanley increased Global-E Online's target to $50 and upgraded it to Overweight. Other notable changes include Truist Financial, Annexon, Ameriprise Financial, Lyft, A O Smith, Hudson Pacific Properties, Boyd Gaming, and Veradermics.
2 min readHC Wainwright & Co. maintained a Buy rating and $25 price target for Annexon, implying a 633.1% upside from the Oct 16 close of $3.41. The firm highlighted Annexon's pipeline targeting unmet medical needs in autoimmune and neurodegenerative diseases.
1 min readLove Douglas (PRESIDENT AND CEO) purchased 26,065 shares of Annexon, Inc. (ANNX) at $3.83 on 2026-09-24.
1 min readAnnexon (ANNX) reported Q2 2026 earnings with R&D expenses of $46.6M, G&A expenses of $10.6M, and a net loss of $55.3M. The company has $209.2M in cash and a $200M credit facility. Key updates include ARCHER II trial progress in geographic atrophy and plans for a BLA submission for tanruprubart in Q4 2026. Management projects funding into 2028.
3 min readAnnexon (ANNX) reported Q2 2026 earnings with R&D expenses of $46.6M, G&A expenses of $10.6M, and a net loss of $55.3M. The company has $209.2M in cash and a $200M credit facility. ARCHER II trial for geographic atrophy enrolled 659 patients, exceeding targets. Tanruprubart for Guillain-Barré syndrome (GBS) is on track for BLA submission in Q4 2026, with positive FORWARD study data. Operations are funded into 2028.
3 min readAnnexon, Inc. reported Q2 2026 updates on tanruprubart and vonaprument. For ARCHER II in geographic atrophy, management added a month 24 primary endpoint alongside month 15, citing over-enrollment and retention. In FORWARD for GBS, management said rapid benefit was reproduced in Western cohorts. Annexon plans FDA BLA submission for GBS in Q4 2024 and has a $200M credit facility extending runway to 2028.
7 min readSimply Wall St reports Annexon (ANNX) shares fell about 6.1% after ARCHER II trial updates for vonaprument, including a shift to dual primary endpoints covering 15 and 24 months for geographic atrophy. The article cites Q2 2026 net loss of $55.35 million and says non-dilutive financing up to $200 million extends its cash runway into 2028.
6 min readAnnexon (NASDAQ:ANNX) reported Q2 call highlights for its complement-targeted therapy tanruprubart in Guillain-Barre syndrome, saying patients showed rapid functional gains and ventilator weaning within days, with adverse events linked to GBS complications. The company also added a 24-month endpoint to ARCHER II for vonaprument, with 15-month review expected in Q4 2026 and results in 2027.
5 min read
